| Efficacy of vedolizumab as induction therapy in refractory IBD patients: a multicenter cohort E Shelton, JR Allegretti, B Stevens, M Lucci, H Khalili, DD Nguyen, J Sauk, ... Inflammatory bowel diseases 21 (12), 2879-2885, 2015 | 220 | 2015 |
| Cancer recurrence following immune-suppressive therapies in patients with immune-mediated diseases: a systematic review and meta-analysis E Shelton, D Laharie, FI Scott, R Mamtani, JD Lewis, JF Colombel, ... Gastroenterology 151 (1), 97-109. e4, 2016 | 161 | 2016 |
| New onset idiosyncratic liver enzyme elevations with biological therapy in inflammatory bowel disease E Shelton, K Chaudrey, J Sauk, H Khalili, R Masia, DD Nguyen, V Yajnik, ... Alimentary pharmacology & therapeutics 41 (10), 972-979, 2015 | 72 | 2015 |
| Safety and Efficacy of Teduglutide (Gattex) in Patients With Crohn's Disease and Need for Parenteral Support Due to Short Bowel Syndrome-associated Intestinal Failure. HH Bharati Kochar, Millie D Long, Edward Shelton, Lorraine Young, Francis A ... Journal of Clinical Gastroenterology, 2016 | 54* | 2016 |
| Late onset Pneumocystis pneumonia in patients receiving rituximab for humoral renal transplant rejection E Shelton, M Yong, S Cohney Nephrology 14 (7), 696-699, 2009 | 51 | 2009 |
| Infliximab, adalimumab and vedolizumab concentrations across pregnancy and vedolizumab concentrations in infants following intrauterine exposure E Flanagan, PR Gibson, EK Wright, GT Moore, MP Sparrow, W Connell, ... Alimentary Pharmacology & Therapeutics 52 (10), 1551-1562, 2020 | 45 | 2020 |
| A randomized controlled study of trimethoprim‐sulfamethoxazole versus norfloxacin for the prevention of infection in cirrhotic patients S Lontos, E Shelton, PW Angus, R Vaughan, SK Roberts, A Gordon, ... Journal of Digestive Diseases 15 (5), 260-267, 2014 | 45 | 2014 |
| Intensive drug therapy versus standard drug therapy for symptomatic intestinal Crohn's disease strictures (STRIDENT): an open-label, single-centre, randomised controlled trial JD Schulberg, EK Wright, BA Holt, AL Hamilton, TR Sutherland, AL Ross, ... The lancet Gastroenterology & hepatology 7 (4), 318-331, 2022 | 40 | 2022 |
| Risk stratification of upper GI bleeding with an esophageal capsule S Chandran, A Testro, P Urquhart, R La Nauze, S Ong, E Shelton, ... Gastrointestinal endoscopy 77 (6), 891-898, 2013 | 38 | 2013 |
| Risk of COVID 19 in patients with inflammatory bowel diseases compared to a control population G Maconi, C Bosetti, A De Monti, RK Boyapati, E Shelton, N Piazza, ... Digestive and Liver Disease 53 (3), 263-270, 2021 | 29 | 2021 |
| Electronic estimations of renal function are inaccurate in solid-organ transplant recipients and can result in significant underdosing of prophylactic valganciclovir J Trevillyan, P Angus, E Shelton, J Whitlam, F Ierino, J Pavlovic, ... Antimicrobial agents and chemotherapy 57 (8), 4058-4060, 2013 | 19 | 2013 |
| A single educational intervention improves pregnancy-related knowledge and emotional health among women with IBD who are pregnant or wish to conceive E Flanagan, EK Wright, MP Sparrow, GT Moore, WR Connell, P De Cruz, ... Inflammatory bowel diseases 27 (12), 1909-1918, 2021 | 12 | 2021 |
| Gastrointestinal: Balloon pancreatitis. E Shelton, P Froomes, MA Fink Journal of Gastroenterology & Hepatology 27 (5), 2012 | 8 | 2012 |
| Immunomodulator use does not prevent first loss of response to anti-TNF therapy in inflammatory bowel disease: long term outcomes in a real-world cohort P Varma, AS Rajadurai, DQ Holt, DA Devonshire, CP Desmond, ... Intern Med J 49, 753-760, 2019 | 6 | 2019 |
| Tu1359 Efficacy of vedolizumab as induction therapy in refractory IBD patients following multiple anti-TNF therapy failures BW Stevens, E Shelton, J Sauk, H Khalili, DD Nguyen, M White-Guthro, ... Gastroenterology 148 (4), S-869, 2015 | 4 | 2015 |
| Impact of a pharmacist‐led thiopurine monitoring service in outpatients with inflammatory bowel disease SE Rodda, KJ Fildes, E Shelton, R Goldberg, GT Moore Internal Medicine Journal 53 (5), 779-786, 2023 | 3 | 2023 |
| Hepatic fibrosis is common in Β Thalassaemia and is associated with current and historical iron loading and Hepatitis C E Shelton, CP Chong, L Shochet Journal of Hepatitis 2, 1-8, 2015 | 3 | 2015 |
| CROHN'S DISEASE STRICTURES RESPOND TO DRUG TREATMENT AND TREAT-TO-TARGET INTENSE COMBINATION THERAPY IS MORE EFFECTIVE THAN STANDARD ANTI-TNF THERAPY. THE STRIDENT RANDOMISED … JD Schulberg, EK Wright, BA Holt, T Sutherland, A Ross, AL Hamilton, ... GASTROENTEROLOGY 160 (6), S92-S93, 2021 | 2 | 2021 |
| Comparison of adalimumab serum drug levels when delivered by pen versus syringe in patients with inflammatory bowel disease. An international, multicentre cohort analysis RD Little, IE Chu, EP van der Zanden, E Flanagan, SJ Bell, PR Gibson, ... Journal of Crohn's and Colitis 13 (12), 1527-1536, 2019 | 2 | 2019 |
| Immunomodulator use does not prevent first loss of response to anti‐tumour necrosis factor alpha therapy in inflammatory bowel disease: long‐term outcomes in a real‐world cohort P Varma, AS Rajadurai, DQ Holt, DA Devonshire, CP Desmond, ... Internal Medicine Journal 49 (6), 753-760, 2019 | 2 | 2019 |
